^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Cancer

    Related cancers:
    13h
    Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers (clinicaltrials.gov)
    P1, N=162, Recruiting, Novartis Pharmaceuticals | N=124 --> 162 | Trial completion date: Jun 2030 --> Jan 2031 | Trial primary completion date: Jun 2030 --> Jan 2031
    Enrollment change • Trial completion date • Trial primary completion date
    14h
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    14h
    NOTABLE-309: Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=156, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab)
    15h
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=405, Recruiting, Lepu Biopharma Co., Ltd. | Phase classification: P1/2 --> P1
    Phase classification
    17h
    Intravital Microscopy in Human Solid Tumors (clinicaltrials.gov)
    P=N/A, N=85, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    17h
    Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (clinicaltrials.gov)
    P1/2, N=183, Recruiting, Tango Therapeutics, Inc. | N=133 --> 183
    Enrollment change
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan • daraxonrasib (RMC-6236) • zoldonrasib (RMC-9805) • vopimetostat (TNG462)
    18h
    USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3. (PubMed, Oncogene)
    Upregulation of STEAP3 suppresses ferroptosis by increasing glutathione levels and reducing lipid peroxidation, ultimately promoting tumor proliferation and gemcitabine resistance. Our study identifies the USP10-IGF2BP3-STEAP3 axis as a critical mechanism underlying chemoresistance in pancreatic cancer, suggesting that targeting USP10 may offer a promising therapeutic strategy for overcoming gemcitabine resistance.
    Journal
    |
    IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • STEAP3 (STEAP3 Metalloreductase)
    |
    gemcitabine
    18h
    Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. (PubMed, J Nucl Med)
    The tumor-to-bone marrow absorbed dose ratio was in the same range for [161Tb]Tb-DOTA-LM3 as for [177Lu]Lu-DOTATOC. The administration of 1 GBq of [161Tb]Tb-DOTA-LM3 was safe for all patients, without relevant adverse events.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    18h
    Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. (PubMed, Gut)
    This study provides a spatially resolved molecular map of IPMN progression, delineating key transcriptomic and immune signatures. These findings advance the understanding of IPMN biology and highlight potential biomarkers for risk stratification and therapeutic strategies.
    Journal
    |
    CLDN1 (Claudin 1) • CEACAM1 (CEA Cell Adhesion Molecule 1) • TFF1 (Trefoil Factor 1) • MUC5AC (Mucin 5AC)
    19h
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    1d
    Vav1 Sustains the Expression of Insulin, PDX1 and miR-375 During Differentiation of hiPSCs to β Cells: A Potential Target to Improve the In Vitro Generation of Insulin-Producing Cells. (PubMed, Tissue Eng Regen Med)
    Our findings suggest the existence of a Vav1/PDX1/miR-375/Akt axis as part of the complex network orchestrating the generation of functional β cells. These insights indicate that strategies aimed at specifically modulating Vav1 levels may positively impact the generation of IPCs in vitro and, ultimately, β cell replacement therapy for T1D.
    Preclinical • Journal
    |
    MIR375 (MicroRNA 375) • PDX1 (Pancreatic And Duodenal Homeobox 1) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1)
    1d
    The dual role of miR-184 in cancer: a systematic review of context-dependent regulation. (PubMed, Mol Biol Rep)
    Key molecular targets and pathways influenced by miR-184, including c-MYC, caspases, and apoptotic signalling, were highlighted. Overall, these findings demonstrate that the function of miR-184 in cancer is context-dependent, shaped by tissue type, molecular environment, and cellular signalling networks.
    Review • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MIR184 (MicroRNA 184)